For decades, itaconate has been known as an immune molecule, something macrophages churn out when they encounter pathogens or inflammation signals. Researchers studied it in the context of immune regulation, watching how it modulates inflammatory responses. Nobody expected it to show up in cancer therapy. But here we are.
A groundbreaking study published in Nature has revealed something unexpected: itaconate plays a critical role in one of the most aggressive forms of brain cancer. The findings don’t just add another chapter to cancer biology. They point toward entirely new treatment strategies for tumors that have long resisted therapy.
The Discovery
The research centers on ependymomas, malignant brain tumors that can develop anywhere in the central nervous system. These tumors are particularly dangerous because they often lack obvious vulnerabilities. Surgery is risky, chemotherapy rarely works, and targeted therapies have been essentially nonexistent.
What caught researchers’ attention was a specific genetic feature present in over 80% of supratentorial ependymomas: a fusion between two genes called ZFTA and RELA. Individually, neither gene causes cancer. But when fused together, they become a powerful oncogenic driver that reshapes cellular metabolism and gene expression.
When scientists examined how this fusion gene rewires cellular machinery, they found something striking. The ZFTA-RELA fusion dramatically increases production of itaconate. In fact, among all the metabolites in these cancer cells, itaconate showed the highest elevation.
This was the first clue that itaconate wasn’t just a passive bystander in cancer. It was actively helping the tumor survive and grow.
How Itaconate Fuels Cancer
The connection between ZFTA-RELA and itaconate production runs deeper than simple overexpression. The fusion protein directly activates the gene encoding ACOD1, the enzyme responsible for making itaconate. This creates a self-reinforcing loop.
But the story gets more intricate. ZFTA-RELA doesn’t just turn on itaconate production. It also enhances glutamine metabolism throughout the cell. Glutamine serves as the raw material that ACOD1 converts into itaconate. By boosting glutamine uptake and processing, the cancer ensures a steady supply of the building blocks it needs.
The fusion protein achieves this through an epigenetic mechanism. It adds silencing marks to the PTEN gene, effectively turning off this tumor suppressor. With PTEN suppressed, the PI3K-AKT signaling pathway stays activated, which in turn drives increased glutamine metabolism.
The cancer essentially engineers its own metabolic infrastructure to keep producing itaconate.
The Epigenetic Connection
Why would a cancer cell invest so heavily in making itaconate? The answer lies in how itaconate affects gene regulation.
Itaconate bears a structural resemblance to D-2-hydroxyglutarate, a well-known oncometabolite produced by IDH-mutant cancers. Like D-2HG, itaconate can inhibit enzymes that modify chromatin. Specifically, it blocks KDM5 family enzymes, which remove methyl groups from histone H3.
When KDM5 activity drops, H3K4me3 marks accumulate across the genome. These marks are associated with active gene promoters. Crucially, they accumulate at the regulatory regions of the ZFTA gene itself, maintaining high expression of the fusion protein.
This creates a closed loop. ZFTA-RELA produces itaconate. Itaconate blocks KDM5. KDM5 inhibition increases H3K4me3 at the ZFTA promoter. More itaconate gets made.
The cancer has essentially hijacked an immune metabolite and repurposed it as an epigenetic anchor, locking in expression of its own driver oncogene.
Therapeutic Implications
The discovery opens several promising avenues for treatment. If itaconate is essential for maintaining ZFTA-RELA expression, then blocking itaconate production should weaken the tumor. This is exactly what the researchers found.
When they used genetic approaches to delete ACOD1 or pharmacological inhibitors to block its activity, several things happened. First, H3K4me3 levels at the ZFTA promoter dropped. Second, ZFTA-RELA protein levels fell. Third, tumor cell growth slowed dramatically. In mouse models, ACOD1 deletion extended survival by approximately fourfold.
Several itaconate-suppressing compounds showed efficacy. Dimethyl itaconate itself, administered as a prodrug, inhibited ACOD1 activity and reduced tumor burden. An experimental compound called IRG1-IN-1 produced similar effects. Perhaps most excitingly, these effects could be achieved without major toxicity to normal tissues.
The finding that dimethyl itaconate could serve as a therapeutic agent is counterintuitive but elegant. The molecule acts as a feedback inhibitor of ACOD1, essentially tricking the enzyme into shutting down its own activity.
Targeting Glutamine Metabolism
Beyond direct itaconate inhibition, the study revealed another vulnerability. ZFTA-RELA tumors are deeply dependent on glutamine metabolism. They import more glutamine than normal cells and process it more aggressively.
When researchers treated tumor-bearing mice with JHU-083, a glutamine antagonist that can cross the blood-brain barrier, tumors shrank and survival improved. Glutamine deprivation or treatment with other metabolic inhibitors also selectively harmed ZFTA-RELA cells while sparing normal neural stem cells.
The therapeutic logic is straightforward. These tumors depend on glutamine to fuel itaconate production. Cut off the glutamine supply, and the whole metabolic-epigenetic circuit collapses.
Combination Strategies
Single-agent approaches rarely achieve lasting results in cancer therapy. The researchers explored combination strategies and found several promising combinations.
Dimethyl itaconate plus JHU-083 showed synergistic effects, suggesting that simultaneously blocking itaconate production and glutamine metabolism hits the tumor from two angles.
The most potent combination paired JHU-083 with a PI3K-mTOR inhibitor. This dual approach attacks both the metabolic drivers and the signaling pathways that sustain them. In mouse models, this combination not only reduced primary tumor growth but also prevented spinal metastases, a major cause of treatment failure in ependymoma patients.
The Broader Significance
The study’s implications extend beyond ependymoma. It demonstrates a general principle: immune regulatory metabolites can be co-opted by cancer cells to serve their own purposes.
Itaconate’s journey from macrophage inflammation regulator to cancer epigenetic driver illustrates how metabolic and epigenetic systems are deeply intertwined. The same molecules that help immune cells respond to threats get repurposed by tumors to maintain their growth programs.
For drug development, the findings identify multiple actionable targets. ACOD1 itself can be inhibited with small molecules. KDM5 enzymes can be blocked with experimental inhibitors. Glutamine metabolism can be disrupted with approved drugs and experimental agents.
Most importantly, the study provides a conceptual framework for thinking about cancer metabolism. Tumors don’t just consume nutrients randomly. They actively sculpt their metabolic environment to create the conditions they need for survival. Understanding these dependencies reveals vulnerabilities that can be exploited therapeutically.
Looking Ahead
Translating these findings into clinical treatments will take time. Mouse models don’t always predict human responses, and the blood-brain barrier presents additional challenges for drug delivery. But the mechanistic clarity of the findings provides a strong foundation for drug development.
Several questions remain. Can ACOD1 inhibitors work in human ependymomas? What about other tumor types that might use similar metabolic-epigenetic circuits? Are there resistance mechanisms that tumors could use to bypass these therapies?
Researchers are already exploring these questions. Clinical trials for related approaches in other cancers may provide relevant data. As understanding of tumor metabolism deepens, additional targets are likely to emerge.
The story of itaconate in cancer therapy is still being written. What began as a puzzling observation, that aggressive brain tumors produce high levels of an immune metabolite, has transformed into a promising therapeutic hypothesis. Dimethyl itaconate and related compounds may eventually offer hope for patients with tumors that have resisted treatment for decades.
FAQ Section:
Q: What is dimethyl itaconate and why is it important in cancer research?
A: Dimethyl itaconate is a derivative of itaconate, a naturally occurring metabolite produced by immune cells during inflammatory responses. Recent research has shown that it can inhibit tumor growth by disrupting a metabolic-epigenetic circuit in certain aggressive brain tumors. Its ability to cross cell membranes and inhibit ACOD1 makes it a promising therapeutic candidate.
Q: What are ependymomas and why are they difficult to treat?
A: Ependymomas are malignant brain tumors that arise in the central nervous system. They are difficult to treat because they often lack clear vulnerabilities, respond poorly to chemotherapy, and are located in surgically risky areas. Over 80% of supratentorial ependymomas contain the ZFTA-RELA fusion, which drives tumor growth through unique metabolic dependencies.
Q: How does itaconate help cancer cells survive?
A: In ZFTA-RELA ependymoma cells, itaconate functions as an epigenetic regulator. It inhibits KDM5 enzymes, which leads to accumulation of histone marks that keep the ZFTA-RELA fusion gene actively expressed. This creates a self-reinforcing loop where the cancer maintains its own driver gene expression through metabolite production.
Q: What is the connection between glutamine metabolism and itaconate in cancer?
A: Glutamine serves as the raw material that cancer cells convert into itaconate through the ACOD1 enzyme. ZFTA-RELA tumors enhance glutamine metabolism to ensure a steady supply of itaconate. This makes them vulnerable to glutamine antagonists, which can starve the tumor of the substrates it needs to maintain its growth-promoting metabolic circuits.
Q: What treatment approaches does this research suggest?
A: The research suggests several therapeutic approaches: ACOD1 inhibitors (including dimethyl itaconate itself), glutamine antagonists, KDM5 inhibitors, and combinations thereof. The most effective combinations in preclinical models paired glutamine antagonists with PI3K-mTOR inhibitors, which showed ability to prevent tumor metastases.
Q: Is dimethyl itaconate currently used to treat cancer?
A: No, dimethyl itaconate is currently in the preclinical research phase. While the compound has shown promising results in animal models, clinical trials in human patients have not yet been conducted. The research provides a foundation for future drug development but is not yet an approved treatment.
Q: What makes this discovery significant for cancer research overall?
A: This study reveals how cancer cells can co-opt immune regulatory metabolites for their own purposes. It demonstrates that understanding tumor metabolism can reveal unexpected therapeutic vulnerabilities. The discovery that an inflammation-associated molecule plays a critical role in maintaining oncogene expression opens new avenues for understanding and treating various cancers.